Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Kyowa Kirin Co's pretax income for the
three
months ended in Jun. 2026 was $146 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $662 Mil.
Kyowa Kirin Co's pretax margin was 16.22%.
During the past 13 years, Kyowa Kirin Co's highest Pretax Margin was 24.62%. The lowest was 12.32%. And the median was 16.90%.
During the past 13 years, Kyowa Kirin Co's highest Pretax Margin was 24.62%. The lowest was 12.32%. And the median was 16.90%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co Pre-Tax Income Related Terms
Kyowa Kirin Co Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $662 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a Pre-Tax Income of $662 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Kyowa Kirin Co and its competitors.
Is Kyowa Kirin Co's Pre-Tax Income too high?
Kyowa Kirin Co's current Pre-Tax Income is $662 Mil. Overall, Kyowa Kirin Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Pre-Tax Income compare to ZTS?
Kyowa Kirin Co's Pre-Tax Income of $662 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Kyowa Kirin Co and its competitors. Kyowa Kirin Co's current Pre-Tax Income is $662 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Fairly Valued. The stock's GF Value™ is $15.15, compared to a current price of $15.80 — trading 4.3% above its estimated fair value. The current Pre-Tax Income is $662 Mil. Kyowa Kirin Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Pre-Tax Income is $662 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be overvalued.
The current stock price of $15.80 is trading 4.3% above its estimated GF Value™ of $15.15.
GuruFocus considers Kyowa Kirin Co to be Fairly Valued.
Key valuation signals for KYKOF:
Pre-Tax Income: $662 Mil
GF Value™: $15.15 vs. price of $15.80 (4.3% above fair value)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
83GF Score
Get the complete analysis for KYKOF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
